The prevalence of anemia in patients with inflammatory bowel disease ranges from 8.8% to
73.7% depending on the patient subpopulation. Anemia, one of many extraintestinal …

Too often anemia is considered a rare or unimportant manifestation in inflammatory bowel
disease (IBD). However, over the last 10 years a number of studies have been conducted …

Anemia is the most common systemic complication of inflammatory bowel disease (IBD); so
common that it is almost invariably not investigated and rarely treated. Several …

The prevalence of extraintestinal manifestations in inflammatory bowel diseases varies from
6% to 46%. The aetiology of extraintestinal manifestations remains unclear. There are …

Ulcerative colitis (UC) and Crohn's disease (CD) constitute the two major groups of
idiopathic disorders in inflammatory bowel disease (IBD). Environmental factors, genetic …

Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD)
treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum …

Despite limited understanding of therapeutic aetiopathogenesis of ulcerative colitis and
Crohn's disease, there is a strong evidence base for the efficacy of pharmacological and …

Purpose The objective of this study was to evaluate the validity and completeness of the
General Practice Research Database (GPRD) as a tool for research into inflammatory bowel …

Background & Aims: This study was performed to quantify the risk of renal disease in
patients using aminosalicylates (5-ASA). Methods: Data from the United Kingdom General …

Background Historically, sulfasalazine (SSZ) and 5-aminosalicylates (5-ASAs) have been a
mainstay of mild-to-moderate ulcerative colitis (UC) remission induction and maintenance …